Immunis

Executive Summary

Immunis is a clinical-stage biotechnology company developing a novel stem cell-derived secretome product, IMM01-STEM, to target the underlying mechanisms of aging and treat age-related muscle and metabolic diseases. Based in Irvine, California, the company aims to improve health span by addressing the root causes of aging. Its lead candidate is currently in Phase 2 clinical trials, focusing on conditions such as sarcopenia and metabolic dysfunction. Immunis’s approach leverages the regenerative potential of stem cell secretions to modulate aging pathways, potentially offering a first-in-class therapy for age-related decline. The company operates in the biologics space and targets a large and growing aging population, positioning it for significant market opportunity if successful.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim data readout for IMM01-STEM60% success
• Q2 2026Completion of patient enrollment for Phase 2 trial80% success
• TBDPartnership or licensing deal for IMM01-STEM30% success